Research advances in B-type natriuretic peptide and its clinical application in the patients with cardiovascular diseases.
10.3881/j.issn.1000-503X.2012.02.016
- Author:
Zhong-ling ZHANG
1
;
Jing-yuan MAO
Author Information
1. Graduate School of Tianjin University of Traditional Chinese Medicine, Tianjin, China.
- Publication Type:Journal Article
- MeSH:
Cardiovascular Diseases;
blood;
diagnosis;
drug therapy;
Humans;
Natriuretic Peptide, Brain;
blood;
physiology;
therapeutic use
- From:
Acta Academiae Medicinae Sinicae
2012;34(2):183-189
- CountryChina
- Language:Chinese
-
Abstract:
B-type natriuretic peptide (BNP) is a plasma marker of left ventricular dysfunction and cardiac volume overload. Currently it is mainly used in the cardiovascular field. BNP is an intrinsic regulator of the embryonic stem cell proliferation, and the reduction in BNP can increase the apoptosis rate. The epitope of N terminal pro-brain natriuretic peptide-BNP is most stable. BNP1-32 has the strongest biological activity but with lower plasma level in heart failure patients. The plasma BNP level plays an important role in the diagnosis, prognosis, hospital admission and mortality of heart failure, and can be used as a monitoring indicator in the treatment of heart failure. The deficiency of corin enzyme in patients with heart failure can cause the increase of cracking pro-BNP. BNP can also provide diagnostic and prognostic information for other populations and diseases. Genetic studies on BNP and its receptors also provide important information. Nesiritide, neutral endopeptidase inhibitors, and vasopeptidase inhibitors of the natriuretic peptide synthesis have been used for the treatment of cardiovascular disorders. However, more reliable and accurate approaches for detecting BNP and N terminal pro-brain natriuretic peptide-BNP require further investigations.
